HRMY vs UNH

Harmony Biosciences maintains a strong core business anchored by WAKIX, with 2026 revenue guidance reiterated at $1.0-$1.04 billion, indicating continued market penetration and robust growth (21.1% YoY revenue growth in Q4 2025). The company's attractive valuation (P/E 11.84, PEG 0.43) and strong average annual earnings growth (32.6%) suggest undervaluation relative to its sector. However, the sig...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...